SF 1126

Drug Profile

SF 1126

Alternative Names: PI3K pan inhibitor - SignalRx Pharmaceuticals; SF1126

Latest Information Update: 06 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Semafore Pharmaceuticals
  • Developer SignalRx Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; DNA activated protein kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • Phase I Hepatocellular carcinoma; Neuroblastoma
  • No development reported Lymphoproliferative disorders; Multiple myeloma; Solid tumours

Most Recent Events

  • 27 Mar 2017 Phase-I clinical trials in Hepatocellular carcinoma (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT03059147)
  • 02 Mar 2017 SignalRX Pharmaceuticals plans a phase I trial for Hepatocellular carcinoma (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (NCT03059147)
  • 07 Nov 2016 Preclinical trials in Hepatocellular carcinoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top